Research Article
Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes
Figure 2
Analysis related to high- and low-TNFRSF14-expression group. (a–e) Pathways with differences. (f–g) Drugs with higher sensitivity in the low-TNFRSF14-expression group.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |